Insider trade

CEO sold ~$6.79M of CYTK shares in the open market

Traded Sep 15, 2026 · Filed Sep 15, 2026

Why it stands out

The boss of Cytokinetics sold $6.79M of Cytokinetics shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEOIndirect holding$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$6,789,210

Shares × reported transaction price

Timing vs results

40 days after results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−5.2%	+1.8%	−7.0%

Past results only. Not a forecast.

Sale of shares of common stock by The Bridget Blum 2026 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the shares sold or the proceeds thereof.

yesterday

Derivative exercise or conversion — not an open-market buy.

Automatic saleyesterday

yesterday

Derivative exercise or conversion — not an open-market buy.